Abstract
In this Backstory, we narrate our journey in establishing a multidisciplinary team for sarcoma research and uncovering vulnerabilities in chondrosarcoma cells associated with their NAD(+) dependencies for survival.(1) Our findings hold promise for exploitation, yielding a synergistic cytotoxic effect when combined with systemic therapy.